THURSDAY, Feb. 26, 2015 (HealthDay News) -- The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, including the kidneys.
Avycaz contains the previously approved antibiotic ceftazidime, and the newer antibacterial drug avibactam, the agency said in a news release.
Approved to help combat antibacterial resistance, Avycaz is sanctioned for people who have limited or no other treatment options, the FDA said.
The most common side effects identified during clinical testing included vomiting, nausea, constipation and anxiety. Users with poor kidney function had more serious adverse reactions including decreased effectiveness and seizures, the agency said. And users allergic to penicillin may be at greater risk of serious skin reactions and anaphylaxis, the FDA warned.
Avycaz is distributed by Actavis, based in Cincinnati.
Visit the FDA to learn more.